GNPX - Genprex, Inc.
IEX Last Trade
0.89
0.003 0.326%
Share volume: 2,069
Last Updated: Fri 27 Dec 2024 08:26:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.89
0.00
0.33%
Fundamental analysis
18%
Profitability
25%
Dept financing
3%
Liquidity
75%
Performance
0%
Performance
5 Days
-4.69%
1 Month
-17.59%
3 Months
139.89%
6 Months
-54.82%
1 Year
-89.77%
2 Year
-11.00%
Key data
Stock price
$0.89
DAY RANGE
$0.88 - $0.90
52 WEEK RANGE
$0.24 - $14.40
52 WEEK CHANGE
-$90.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: J. Rodney Varner
Region: US
Website: genprex.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: genprex.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
Recent news